Eurofins Optimed
Gières, France
NCT Number: NCT01544829
The main aim of this study is to determine whether there is a difference in the physiological effects of theobromine when provided via a single serving compared to multiple servings adding up to the same amount of theobromine provided on a day.
This study also aims to study the pharmacokinetics of theobromine after administration once per day versus administration 4 times per day.
Hypothesis: the effects on heart rate are less pronounced when a high dose of theobromine is given in 4 smaller doses.
Looking for future studies?
Notify Me40 year–70 year
All sexes
Interventional
Not applicable
Gières, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single dose of theobromine
Placebo capsules
Time frame: 3 days
Measured during 24h (every 15 minutes during the day and every 30 minutes during the night) for 3 periods
Time frame: Measured during 24h (every 15 minutes during the day and every 30 minutes during the night) for 3 periods
Time frame: Measured on day 1 and 2 (at time points -5min and 24h) for 3 periods
Time frame: Measured on day 1 and 2 (at time points -5min and 24h) for 3 periods
Time frame: Measured on day 1 and 2 (at time points -5min, 3h, 5h, 10h and 24h) for 3 periods
Unilever R&D
Industry
The Acute Effect of 2 Different Serving Regimens of Theobromine on Theobromine Concentration in the Blood & Physiological Effects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT05882045
Body Weight, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT02439775
Cardiovascular Diseases, Hypertension
Huntsville, Alabama, United States
View Trial DetailsNCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial Details